Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025)
Raphael Pharmaceutical's (RAPH) quarterly Cash from Financing Activities came in at -$4000.0 in Q4 2025, down 109.76% year-over-year from $41000.0 in Q4 2024, and down 101.67% quarter-over-quarter from $240000.0 in Q1 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Cash from Financing Activities across 6 years of filings, most recently posting -$4000.0 for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 109.76% year-over-year to -$4000.0; the TTM figure through Dec 2025 stood at $236000.0 (down 26.48% YoY), while the FY2025 annual figure was $236000.0, down 26.48% from the prior year.
- Cash from Financing Activities came in at -$4000.0 for Q4 2025 at Raphael Pharmaceutical, down from $240000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $820000.0 in Q4 2021 to a low of -$4000.0 in Q4 2025.
- Average Cash from Financing Activities over 5 years is $239705.9, with a median of $149000.0 recorded in 2023.
- Year-over-year, Cash from Financing Activities soared 1390.0% in 2023 and slumped 109.76% in 2025.
- Over 5 years, Cash from Financing Activities stood at $820000.0 in 2021, then sank by 42.44% to $472000.0 in 2022, then slumped by 95.97% to $19000.0 in 2023, then surged by 115.79% to $41000.0 in 2024, then tumbled by 109.76% to -$4000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$4000.0 in Q4 2025, $240000.0 in Q1 2025, and $41000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -4,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Dec 31, 2022 | 472,000.00 |
| Sep 30, 2022 | 112,000.00 |
| Jun 30, 2022 | 302,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 820,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 513,000.00 |
| Mar 31, 2021 | 44,000.00 |
| Dec 31, 2020 | 527,000.00 |